Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for use of Sentinel node biopsy

References

1 National Breast Cancer Centre*. Clinical practice guidelines for the management of early breast cancer. 2nd Edition. Canberra: Commonwealth of Australia 2001.

2 Australian Institute of Health and Welfare & National Breast Cancer Centre*. Breast cancer survival by size and nodal status in Australia. Canberra: AIHW 2007.

3 National Breast and Ovarian Cancer Centre*. Sentinel node biopsy for early breast cancer: a systematic review. National Breast and Ovarian Cancer Centre*, Surry Hills, NSW, 2008.

4 Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546–53.

5 Veronesi U, Paganelli G, Viale G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7(12):983–90.

6 Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial. J Natl Cancer Inst. 2006;98(9):599–609.

7 Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95(3):279–93.

8 Gill P, Gebski V, Wetzig N, et al. Sentinel node (SN) based management causes less arm swelling and better quality of life than routine axillary clearance (AC): 1 year outcomes of the SNAC trial. San Antonio Breast Cancer Symposium. 2006; Abstract;27.

9 Julian T, Krag D, Brown A, et al. Preliminary technical results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. San Antonio Breast Cancer Symposium. 2004;Abstract 14.

10 Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23(19):4312–21.

11 Zavagno G, De Salvo G, Scalco G, et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer. Results of the sentinella/GIVOM trial. Ann Surg. 2008; 247(2):207-213.

12 Del Bianco P, Zavagno G, Burelli P, et al. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: Results of the sentinella-GIVOM Italian randomised clinical trial. Eur J Surg Oncol. Published online 5 Jul 2007; doi:10.1016/ j.ejso.2007.05.017:1–6.

13 Radovanovic Z, Golubovic A, Plzak A, Stojiljkovic B, Radovanovic D. Blue dye versus combined blue dye-radioactive tracer technique in detection of sentinel lymph node in breast cancer. Eur J Surg Oncol. 2004;30(9):913–7.

14 Hung WK, Chan CM, Ying M, et al. Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer. Br J Surg. 2005;92(12):1494–7.

15 Meyer-Rochow GY, Martin RC, Harman CR. Sentinel node biopsy in breast cancer: validation study and comparison of blue dye alone with triple modality localization. ANZ J Surg. 2003;73(10):815–8.

16 Rodier J, Velten M, Wilt M, et al. Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures: FRANSENODE trial. J Clin Oncol. Published online 7 May 2007; doi:10.1200/JCO.2006.08.4228.

17 Povoski SP, Olsen JO, Young DC, et al. Prospective randomized clinical trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol. 2006;13(11):1412–21.

18 Lucci A, Mackie McCal L, Beitsch P, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. Published online 7 May 2007; doi:10.1200/JCO.2006.07.4062.

19 National Health and Medical Research Council. How to use the evidence: assessment and application of scientific evidence. Canberra: Commonwealth of Australia 2000.

20 Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel lymph node resection and conventional axillary lymph node dissection in patients with clinically node negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881–88.***

21 Harlow SP, Krag DN, Julian TB, et al. Prerandomization Surgical Training for the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 trial: a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer. 2005;241(1):48–54.

22 Ung O. Australasian experience and trials in sentinel lymph node biopsy: The RACS SNAC trial. Asian J Surg. 2004;27(4):284–90.

23 National Breast and Ovarian Cancer Centre* and Australian Cancer Network. The pathology reporting of breast cancer. A guide for pathologists, surgeons, radiologists and oncologists. 3rd edition. National Breast and Ovarian Cancer Centre*, Surry Hills, NSW, 2008.

24 Medical Services Advisory Committee. Sentinel Lymph Node Biopsy in Breast Cancer: Commonwealth of Australia; 2005. MSAC reference 1065.

25 National Breast Cancer Centre* and National Cancer Control Initiative. Clinical practice guidelines for the psychosocial care of adults with cancer. Canberra: Commonwealth of Australia 2003.

26 Theraputic Goods Administration. Patent blue V and anaphylaxis. Australian Adverse Drug Reactions Bulletin 2002.

27 Wetzig NR, Gill PG, Ung O, et al. Participation in the RACS sentinel node biopsy versus axillary clearance trial. ANZ J Surg. 2005;75(3):98–100.

28 Australian New Zealand Clinical Trials Registry. SNAC II. Accessed: November 2007; Available at: http://www.anzctr.org.au/trial_view.aspx?ID=484

29 National Cancer Institute Clinical Trials PDQ. EORTC-10981-AMAROS. Accessed: June 2007; Available at: http://www.cancer.gov/clinicaltrials/EORTC-10981

30 National Cancer Institute Clinical Trials PDQ. IBCSG-23-01. Accessed: June 2007; Available at: http:// www.cancer.gov/clinicaltrials/IBCSG-23-01

31 Australian New Zealand Clinical Trials Registry. SNAC I. Accessed: February 2008; Available at: http://www.anzctr.org.au/trial_view.aspx?ID=448

***This article was considered by the NBOCC’s* Sentinel Node Biopsy Subgroup but published after July 2007

* In February 2008, National Breast Cancer Centre (NBCC), incorporating the Ovarian Cancer Program, changed its name to National Breast and Ovarian Cancer Centre (NBOCC). In July 2011, NBOCC amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

Published using CeCC Docbook Manager